Discover the forefront of diabetes care, targeting the latest in once-weekly basal insulin therapy, including unique mechanism of action and pharmacokinetic/pharmacodynamic properties. Unpack recent safety and efficacy data. Additionally, hear discussion about basal insulin therapy for patient care and how to best ensure adherence through effective T2D management. Delve into clinical trials outcomes, glycemic control, weight management, and hypoglycemia risks. Engage in essential scientific discourse to shape the future of diabetes treatment. Particpate in this program for an insightful blend of data and practice.

Academic and community health care practitioners, including endocrinologists and diabetologists, endocrinology clinical researchers, fellows, and allied health professionals (nurse practitioners (NPs), PAs, nurses, and pharmacists) who provide care for individuals with diabetes.

Upon completing this activity, learners should be able to: 

• Assess the current limitations that exist with traditional insulin therapies to support the rationale for the emerging role of novel therapies with unique MOA and pharmacokinetic/ pharmacodynamic properties.
• Evaluate the latest efficacy and safety data for new and emerging options for basal insulin therapy in T2D management, including once-weekly versus once-daily basal insulin formulations.
• Develop a comprehensive approach to incorporate basal insulin therapy into T2D treatment plans in accordance with current guidelines, emphasizing the need for individualized care and shared decision-making approaches to facilitate improved patient outcomes.
• Recognize the importance of early patient education and the impact of non-adherence to basal insulin therapy on T2D management 

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Endocrine Society and The Medical Learning Institute. The Endocrine Society is accredited by the ACCME to provide continuing medical education for physicians. 

AMA PRA Category 1 Credit

The Endocrine Society designates each activity in this course for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC)
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.50 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Thomas Pieber, MD, Program Chair: Professor of Medicine and Head of the Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University Graz; Director of the Institute of Biomedicine and Health Sciences, Joanneum Research, Graz, Austria.

Devin Steenkamp, MBChB: Assistant Professor of Medicine, Section of Endocrinology, Diabetes and Nutrition, Boston University School of Medicine, Director of Clinical Diabetes, Boston Medical Center, Boston, MA

Eda Cengiz, MD, MHS: Professor of Pediatricts, UCSF Endocrinology Department of Pediatrics, University of California San Francisco, San Francisco, CA

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Thomas Pieber, MD: Arecor, Eli Lilly, Sanofi, Advisory Board; Novo Norkisk, Consultnat, Speaker; Roche, Speaker.

Devin Steenkamp, MBChB: Abbott Diabetes Care, Consultant

Eda Cengiz, MD, MHS: Novo Norkisk, Eli Lilly, Adocia, Arecor, Provention Bio, Portal Insulin, Mannkind, Scientific Advisory Board Member and Consultant

The following faculty reported no relevant financial relationships: N/A

The following committee member who planned and reviewed content for this activity reported no relevant financial relationships: 

Milay Luis Lam, MD 

The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.

The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.

Acknowledgement of Commercial Support:
This educational activity is supported by an educational grant from Novo Nordisk.